1. People might not take it
Assuming a Covid-19 vaccine meets FDA and WHO benchmarks, which include such stipulations as “vaccine benefits outweigh safety risks,” the public still needs to be convinced to take the shot. That’s not a given.
In May, an Associated Press poll found less than 50% of Americans planned to take an approved and available Covid-19 vaccine, similar to the findings of a Pew Research Center poll conducted later that month.
The most recent numbers show patients and healthcare professionals are divided on the issue of when and if to get vaccinated. The opinion poll, made available to the 10,000-plus subscribers of Monthly Musings on American Healthcare asked: “At what point would you feel comfortable getting vaccinated for Covid-19?”
An opinion survey on vaccine development, approval and administration in the United States. According to the results, more than half of people working in healthcare would be willing to get vaccinated upon FDA approval. In contrast, 61% of patients prefer to wait for more definitive proof of the vaccine’s safety and efficacy.
That would present a problem. To eliminate the virus, nearly all the whole population needs to be vaccinated or acquire antibodies through infection and recovery. Otherwise, the disease will simmer indefinitely.
2. Immunity might not last
Historically, some strains of coronavirus, like the kind that causes the common cold, fail to produce long-lasting antibodies. By contrast, people who recover from the more lethal coronaviruses, such as severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), produce antibodies that last two to three years.
So what about SARS-CoV-2, the virus causing the current pandemic? Results of a study published in Nature observed that antibody levels fall off just two to three months after infection. Likewise, a New England Journal of Medicine report last month noted antibody levels in Covid-19 survivors dropped rapidly within months. That same report suggested people who recover from the disease could be left without any antibodies within one year.
As scientists seek to better understand the immune status of people who recover from Covid-19, much remains unknown. Do lower antibody counts indicate the end of immunity? How will these antibodies respond when re-exposed to the virus and are antibody levels higher in people who had severe infection? Also, is a second illness from Covid-19 possible or were past scares of reinfection merely the result of faulty antibody (serology) testing?
With so much confusion surrounding the immune status of people who’ve recovered from the infection itself, scientists fear there will be even less certainty concerning a vaccine’s true efficacy.
3. The vaccine might not work
The U.S. government’s Operation Warp Speed, which launched in June, pledged $10 billion toward developing and delivering 300 million doses of a safe, effective Covid-19 vaccine by January 2021. The race is on and some early leaders have drummed up significant media excitement over the possibility of bringing a vaccine to market in record time.
As I wrote in Forbes last month, Americans assume a cure will materialize from a combination of public urgency and heavy research funding. Few realize that the currently accepted timeline for a coronavirus vaccine is based more on medical optimism than scientific evidence.
Major drug companies like Pfizer, Moderna and others vying to create a Covid-19 cure are relying on a method that has not produced a safe or effective mRNA vaccine against any viral infection in more than two decades of research.
4. The vaccine gets approved but might be only 50% effective
In the past, successfully developed vaccines used inactivated or attenuated (weakened) viruses and proved highly effective. For example, three doses of the polio vaccine is nearly 100 percent effective while the vaccine for measles is 93 percent effective after just one dose (and 97%-plus after two doses), according to the CDC.
Many vaccines, however, aren’t designed to deliver lifelong protection at near-universal rates. For example, the CDC conducts studies each year about the effectiveness of the seasonal flu shot at protecting people against various strains. And because the flu virus mutates from year to year, statistics show the vaccine is between 40% to 60% effective at reducing the risk of flu-like illness.
That brings us to the novel coronavirus. In April, the WHO noted the ideal vaccine would establish immunity in at least 70 percent of the population, including the elderly. In July, an FDA official added, “We’re going to need a vaccine that’s probably in the order of 70% effective and 70%, at least, of the population is going to need to take it.” Meanwhile, Dr. Fauci is on the record as saying that he, too, would settle for a 70% to 75% effective vaccine.
But those are all “ideal” situations. =FDA guidance issued in June stated, “To ensure that a widely deployed COVID-19 vaccine is effective, the primary efficacy endpoint point estimate for a placebo-controlled efficacy trial should be at least 50%.”
This possibility leads to some disheartening mathematics. Assuming that only 50% of the population takes a vaccine that is only 50% effective, the nation’s immunization rate could be as low as 25%. That total would be insufficient to end the pandemic.
Achieving herd immunity, the point at which the virus would no longer spread, would require at least 70% of the country (200 million Americans) to either be vaccinated or acquire the virus and recover from it. Further, that estimate assumes long-lasting immunity from the virus.
5. Something unexpected happens
For all that scientists don’t know about Covid-19 (the disease), they do know that the coronavirus (which causes the disease) has behaved predictably, far more predictably than humans.
When people wear masks, physically distance and wash their hands, the curve of infection either flattens or declines. When people gather indoors or in large groups without masks, cases rise exponentially.
In that respect, we’ve seen no major surprises out of the pathogen so far. But could that change, too?
Immunologists have observed that the virus has exhibited no major or concerning mutations since reaching U.S. shores. But, theoretically, it could. And a virus that mutates significantly over time could render an approved vaccine ineffective.
Content created and supplied by: Newsgod (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More